CME and CFTC Clash Over On-Chain Perpetual Futures

The CME Group, the largest derivatives exchange operator in the US, is locked in a battle with its regulator, the Commodity Futures Trading Commission, over the introduction of blockchain-based perpetual futures products. The CFTC recently approved the listing of crypto perpetual futures, also known as perps, on the prediction markets platform Kalshi and cryptocurrency exchange Coinbase, but the CME is challenging this decision, arguing that these products are harmful to its traditional futures contracts and that the CFTC is mislabeling them. The CME claims that perps, which allow users to speculate on the price of an asset with leverage and no expiration date, are swaps rather than futures and should be subject to different regulatory requirements. The dispute between the CME and the CFTC has significant implications for the US approach to the rapidly growing market for perpetual futures, with non-US perps volume reportedly reaching $60 trillion in volume last year. The CME's lawsuit against the CFTC and its chairman, Mike Selig, challenges the agency's decision to allow the listing of perps and alleges that it did not consider the potential consequences. The CFTC has declined to comment on the matter, but its chairman has stated that the CME's decision to disregard the agency's efforts to undertake a reasoned analysis of the issues at stake is 'wholly inappropriate'. The CME's CEO, Terry Duffy, has argued that the CFTC's approval of perps is a departure from the law and that the agency is not prepared to enforce its emerging perps policy properly. The dispute has sparked a heated debate, with some arguing that the CME is trying to stifle innovation and competition, while others see the CFTC's approach as a threat to the stability of the financial system. The outcome of the lawsuit is likely to have significant implications for the future of the perps market in the US and beyond.